Form 4: Paragon 28 CFO Chadi Chahine Reports Disposition of Shares and Derivative Securities Following Merger with Zimmer Biomet

Chadi Chahine, CFO of Paragon 28, reports the disposition of common stock and performance stock units due to the merger with Zimmer Biomet, where each share was converted into cash and a contingent value right.

Summary

• Chadi Chahine, the Chief Financial Officer and EVP of Supply Chain Operations at Paragon 28, filed a Form 4 detailing changes in beneficial ownership.
• The filing is related to the merger between Paragon 28 and Zimmer Biomet Holdings, Inc., which became effective on April 21, 2025.
• As a result of the merger, Mr. Chahine disposed of 520,657 shares of common stock.
• Additionally, 174,769 performance stock units (PSUs) were disposed of.
• Each share of common stock was converted into the right to receive $13.00 in cash and one contingent value right (CVR).
• The PSUs vested at 140% of the target number of shares and were also converted into cash and CVRs.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as the merger has been completed, and the filing reflects the expected outcome. There are no indications of distress or negative surprises.

Future Outlook

The document does not contain specific forward-looking statements beyond the completion of the merger.

Industry Context

This announcement reflects a continuation of consolidation trends within the medical device industry, where larger companies acquire smaller, specialized firms to expand their product portfolios and market reach.

Stakeholder Impact

• Shareholders received $13.00 in cash and one CVR per share.
• Management and employees are now part of Zimmer Biomet.

Key Dates

Keywords

Form 4, Paragon 28, Zimmer Biomet, Merger, Chadi Chahine, Disposition, Common Stock, Performance Stock Units, CVR